Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | BER | PATIENT: |
|-------|-----------------|-----|--|
| Name | e: | | Name: |
| Ward: | : | | NHI: |
| Viga | batri | in | |
| Re-a | | men | required after 15 months tick boxes where appropriate) |
| | | or | O Patient has infantile spasms |
| | | | O Patient has epilepsy and |
| | | | Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents |
| | | or | O Patient has tuberous sclerosis complex |
| | and | | |
| | | or | Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter) |
| | | | O It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields |
| | ITINU/ equis | | N tick boxes where appropriate) |
| | and | 0 | The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life |
| | | or | O Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin |
| | | | O It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields |
| | | | |

I confirm that the above details are correct:

Signed: Date: